resolutivesp/covermap

Open decision tool that turns published antivenom-neutralisation evidence into auditable procurement plans: which product, at which named hospital, how many vials, at what cost. Four country demonstrators (Ghana, Nigeria, India, Kenya) · 285 automated checks · full provenance audit. Feasibility demonstrator — not clinical guidance. # CoverMap **Matching antivenom to the snakes that actually bite.** Antivenom is species-specific: the wrong product does not save the patient. When a rural Ghanaian hospital switched from an effective antivenom to an unsuitable one against the carpet viper, case-fatality among treated patients rose **1.8% → 12.1%** (Visser 2008). CoverMap joins **what bites where** → **what each product is actually proven to neutralise** → **who can reach care**, and returns a named, costed pre-positioning plan: which facility should stock which antivenom, how many vials, at what annual cost. **→ Open the live tool** — four countries, every number re-derived from open data. *Red is expected burden. Blue marks the named hospitals the optimiser selects. Click the maps to open the live tool.* --- ## Four countries, three failure regimes | | Headline | Demand forecast | |---|---|---| | **Ghana** | **86.0%** of the carpet-viper burden brought within reach via 25 hospitals | 4,654 vials/yr (~$371,114) | | **Nigeria** | **85.5%** via 63 hospitals — the same method against the largest West-African burden | 36,671 vials/yr (~$2,931,101) | | **India** | **36.8%** of burden where the standard ASV likely underperforms (~20,484 deaths/yr inside that gap) | targeting list | | **Kenya** | **86.6%** of expected attendances via 45 hospitals — the failing products were already withdrawn (2022); the gap is availability and placement | 1,569 vials/yr (~$125,520) | In West Africa the binding gap is **which product** is stocked and where. In India a single southern-sourced polyvalent is used nationwide, so the gap is **regional venom variation and non-Big-Four species**. In Kenya the product triage is already done — the failing brands were withdrawn in 2022 after national QC testing — so the gap is **availability and placement**. The same engine expresses all three. --- ## Honest by design This is a **feasibility demonstrator (IML 2)**, not a validated system, and it is built to say so. - …